메뉴 건너뛰기




Volumn 68, Issue 1, 2013, Pages 57-63

Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice

Author keywords

biologics; daily practice; etanercept; long term efficacy; method of analysis; psoriasis; registry

Indexed keywords

ETANERCEPT;

EID: 84870933748     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2012.05.040     Document Type: Article
Times cited : (19)

References (13)
  • 2
    • 84855835696 scopus 로고    scopus 로고
    • Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population
    • Epub 2010 Sep 17
    • K.A. Papp, Y. Poulin, R. Bissonnette, M. Bourcier, D. Toth, and L. Rosoph Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population J Am Acad Dermatol 66 2012 e33 e45 Epub 2010 Sep 17
    • (2012) J Am Acad Dermatol , vol.66
    • Papp, K.A.1    Poulin, Y.2    Bissonnette, R.3    Bourcier, M.4    Toth, D.5    Rosoph, L.6
  • 3
    • 34250761386 scopus 로고    scopus 로고
    • Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis
    • S. Tyring, K.B. Gordon, Y. Poulin, R.G. Langley, A.B. Gottlieb, and M. Dunn Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis Arch Dermatol 143 2007 719 726
    • (2007) Arch Dermatol , vol.143 , pp. 719-726
    • Tyring, S.1    Gordon, K.B.2    Poulin, Y.3    Langley, R.G.4    Gottlieb, A.B.5    Dunn, M.6
  • 4
    • 77956037959 scopus 로고    scopus 로고
    • The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab
    • M. Papoutsaki, M. Talamonti, A. Giunta, A. Costanzo, M. Ruzzetti, and M. Teoli The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab Dermatology 221 Suppl 1 2010 43 47
    • (2010) Dermatology , vol.221 , Issue.SUPPL.. 1 , pp. 43-47
    • Papoutsaki, M.1    Talamonti, M.2    Giunta, A.3    Costanzo, A.4    Ruzzetti, M.5    Teoli, M.6
  • 5
    • 0035726025 scopus 로고    scopus 로고
    • Differences in efficacy between intention-to-treat and per-protocol analyses for patients with psoriasis vulgaris and atopic dermatitis: Clinical and pharmacoeconomic implications
    • R. Schiffner, J. Schiffner-Rohe, M. Gerstenhauer, F. Hofstadter, M. Landthaler, and W. Stolz Differences in efficacy between intention-to-treat and per-protocol analyses for patients with psoriasis vulgaris and atopic dermatitis: clinical and pharmacoeconomic implications Br J Dermatol 144 2001 1154 1160
    • (2001) Br J Dermatol , vol.144 , pp. 1154-1160
    • Schiffner, R.1    Schiffner-Rohe, J.2    Gerstenhauer, M.3    Hofstadter, F.4    Landthaler, M.5    Stolz, W.6
  • 6
    • 0018099294 scopus 로고
    • Severe psoriasis - Oral therapy with a new retinoid
    • T. Fredriksson, and U. Pettersson Severe psoriasis - oral therapy with a new retinoid Dermatologica 157 1978 238 244
    • (1978) Dermatologica , vol.157 , pp. 238-244
    • Fredriksson, T.1    Pettersson, U.2
  • 7
    • 77957021919 scopus 로고    scopus 로고
    • Switching from etanercept to adalimumab is effective and safe: Results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept
    • P.P. Van Lumig, L.L. Lecluse, R.J. Driessen, P.I. Spuls, J.B. Boezeman, and P.C. van de Kerkhof Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept Br J Dermatol 163 2010 838 846
    • (2010) Br J Dermatol , vol.163 , pp. 838-846
    • Van Lumig, P.P.1    Lecluse, L.L.2    Driessen, R.J.3    Spuls, P.I.4    Boezeman, J.B.5    Van De Kerkhof, P.C.6
  • 10
    • 21644481166 scopus 로고    scopus 로고
    • A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction
    • K.A. Papp, S. Tyring, M. Lahfa, J. Prinz, C.E. Griffiths, and A.M. Nakanishi A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Br J Dermatol 152 2005 1304 1312
    • (2005) Br J Dermatol , vol.152 , pp. 1304-1312
    • Papp, K.A.1    Tyring, S.2    Lahfa, M.3    Prinz, J.4    Griffiths, C.E.5    Nakanishi, A.M.6
  • 11
    • 29844440963 scopus 로고    scopus 로고
    • Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial
    • S. Tyring, A. Gottlieb, K. Papp, K. Gordon, C. Leonardi, and A. Wang Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial Lancet 367 2006 29 35
    • (2006) Lancet , vol.367 , pp. 29-35
    • Tyring, S.1    Gottlieb, A.2    Papp, K.3    Gordon, K.4    Leonardi, C.5    Wang, A.6
  • 12
    • 79958096534 scopus 로고    scopus 로고
    • Intention to treat analysis, compliance, drop-outs and how to deal with missing data in clinical research: A review
    • S. Armijo-Olivo, S. Warren, and D. Magee Intention to treat analysis, compliance, drop-outs and how to deal with missing data in clinical research: a review Physical Therapy Reviews 14 2009 36 49
    • (2009) Physical Therapy Reviews , vol.14 , pp. 36-49
    • Armijo-Olivo, S.1    Warren, S.2    Magee, D.3
  • 13
    • 79955386416 scopus 로고    scopus 로고
    • Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris
    • R. Gniadecki, K. Kragballe, T.N. Dam, and L. Skov Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris Br J Dermatol 164 2011 1091 1096
    • (2011) Br J Dermatol , vol.164 , pp. 1091-1096
    • Gniadecki, R.1    Kragballe, K.2    Dam, T.N.3    Skov, L.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.